Compare Neurocrine Biosciences Inc (NBIX) vs iShares 20 Plus Year Treasury Bond ETF (TLT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs iShares 20 Plus Year Treasury Bond ETF — how do they compare? Neurocrine Biosciences Inc trades at $157.69 (market cap $16.46B), while iShares 20 Plus Year Treasury Bond ETF trades at $82.29. The key difference: Neurocrine Biosciences Inc is trading nearer its 52-week high, iShares 20 Plus Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| NBIX | TLT | |
|---|---|---|
Market Cap | $16.46B | — |
Sector | Health | — |
52-Week High | $185.50 | $92.06 |
52-Week Low | $123.10 | $82.05 |
Enterprise Value | $16.48B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $158.89, down 3.66% in the past 24 hours, reflecting near-term bearish technical signals. The stock shows strong fundamentals with Q2 2026 revenue growth of 39% year-over-year to $959 million and a net income margin of 20.91%. Recent news highlights include positive clinical data for INGREZZA and the initiation of a Phase 1 study for a GLP-1/GIP/glucagon receptor triple agonist, though safety concerns were raised for Vykat XR in Prader-Willi Syndrome.
The outlook remains positive given robust earnings beats, raised 2026 sales guidance, and a consensus price target of $208.82 implying significant upside. Risks include clinical trial setbacks, competitive pressures, and regulatory scrutiny. Analyst sentiment is strongly bullish with 86% buy ratings, supporting a growth-oriented investment case amid near-term volatility.
TLT, the iShares 20+ Year Treasury Bond ETF, trades at $82.40, up 0.43% on the day, amid a bearish technical signal with selling pressure dominating moving averages. Recent news highlights rising Treasury yields and inflation concerns, with institutional buying noted. The ETF provides exposure to long-term U.S. government bonds, with dividend distributions continuing regularly.
Outlook remains cautious due to interest rate uncertainty and inflation pressures, offering income but facing headwinds from potential Fed policy shifts. Key risks include yield volatility and macroeconomic factors impacting bond prices.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About iShares 20 Plus Year Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index. The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity greater than or equal to twenty years.
Read more on TLT →
